Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave, Mitsubishi Form Joint Venture to Develop PGx-Based Diagnostics

NEW YORK, April 6 (GenomeWeb News) - Third Wave Technologies and Mitsubishi have formed a joint venture for personalized medicine in Japan and the Asia-Pacific region, the companies said yesterday.

 

The joint venture, Third Wave Japan, plans to develop products for the Japanese molecular diagnostic market, including tests for diagnosing infectious diseases and products to improve drug safety and efficacy.

 

Third Wave will hold worldwide rights outside the Asia-Pacific region to any new technology or product developed by Third Wave Japan.

 

Third Wave Japan and Mitsubishi also plan to accelerate the penetration of Third Wave's Invader products in clinical laboratories in the region, especially in Japan.

 

Mitsubishi has a 14-percent minority investment in Third Wave Japan. In addition, CSK Holdings, through its new subsidiary CSK Institute for Sustainability, will hold a 3-percent stake in the joint venture.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.